02126 藥明巨諾－Ｂ
按盘价 
1.670 +0.020 (+1.212%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | -30.871% | -31.109% | -28.644% | -20.369% | -74.809% |
| 股东资金回报率 (%) | -41.404% | -38.037% | -32.891% | -22.581% | -133.779% |
| 资本运用回报率 (%) | -48.599% | -40.816% | -34.111% | -24.071% | -46.968% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 48.867% | 50.743% | 40.326% | 29.370% | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -334.722% | -408.921% | -529.212% | -2150.482% | N/A |
| 税前边际利润率 (%) | -373.298% | -441.743% | -580.730% | -2280.508% | N/A |
| 纯利率 (%) | -373.298% | -441.743% | -580.730% | -2280.508% | N/A |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 1.739 X | 4.036 X | 4.778 X | 9.528 X | 11.168 X |
| 速动比率 (X) | 1.672 X | 3.905 X | 4.649 X | 9.370 X | 11.164 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 30.422% | 21.540% | 15.658% | 10.452% | 9.254% |
| 总债项 / 总资产比率 (%) | 25.138% | 14.855% | 10.000% | 4.718% | 3.270% |
| 净债项 / 总资产比率 (%) | -19.934% | -32.017% | -39.558% | -54.141% | -66.332% |
| 总债项 / 股东资金比率 (%) | 36.129% | 18.933% | 11.856% | 5.268% | 3.604% |
| 长期债项 / 股东资金比率 (%) | 3.947% | 11.746% | 5.362% | 4.545% | 3.286% |
| 净债项 / 股东资金比率 (%) | -28.650% | -40.806% | -46.902% | -60.460% | -73.096% |
| 净现金 / (债项) ($) | 3.35亿 | 6.87亿 | 11.04亿 | 16.87亿 | 25.07亿 |
| 每股净现金 / (债项) ($) | 0.806 | 1.666 | 2.686 | 4.139 | 6.463 |
| 总债项 / 资本运用比率 (%) | 34.757% | 16.943% | 11.253% | 5.039% | 3.489% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 148.963日 | 159.697日 | 150.207日 | 271.476日 | -- |
| 应收贸易帐周转率日数 (日) | N/A | N/A | 13.290日 | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 6.211日 | 11.414日 | 12.737日 | 20.545日 | N/A |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -590,624,000 |
| 增长率 | -23.095% |
| 每股盈利/(亏损) | RMB -1.430 |
| 每股账面资产净值 (¥) | RMB 2.814 |